Back to Search
Start Over
Discovery, development and application of drugs targeting BCL-2 pro-survival proteins in cancer
- Source :
- Biochemical Society Transactions
- Publication Year :
- 2021
- Publisher :
- Portland Press Ltd., 2021.
-
Abstract
- The discovery of a new class of small molecule compounds that target the BCL-2 family of anti-apoptotic proteins is one of the great success stories of basic science leading to translational outcomes in the last 30 years. The eponymous BCL-2 protein was identified over 30 years ago due to its association with cancer. However, it was the unveiling of the biochemistry and structural biology behind it and its close relatives’ mechanism(s)-of-action that provided the inspiration for what are now known as ‘BH3-mimetics’, the first clinically approved drugs designed to specifically inhibit protein–protein interactions. Herein, we chart the history of how these drugs were discovered, their evolution and application in cancer treatment.
- Subjects :
- BCL-2
Antineoplastic Agents
Cell Death & Injury
Bcl-xL
Close relatives
Ligands
Bioinformatics
Biochemistry
Drug Delivery Systems
BCL-XL
Drug Discovery
Chemical Biology
Humans
Medicine
Review Articles
Cancer
Bh3 mimetics
Molecular Interactions
biology
business.industry
Mechanism (biology)
Molecular Mimicry
apoptosis
BH3-mimetics
medicine.disease
Therapeutics & Molecular Medicine
Small molecule
Cancer treatment
Proto-Oncogene Proteins c-bcl-2
Structural biology
biology.protein
MCL-1
business
Subjects
Details
- ISSN :
- 14708752 and 03005127
- Volume :
- 49
- Database :
- OpenAIRE
- Journal :
- Biochemical Society Transactions
- Accession number :
- edsair.doi.dedup.....dfdfd504a1cd04dbde6f7dd388d2eec1